NeuroBo's DA-1241 Plus Semaglutide Enhances Liver Fibrosis and Hepatoprotection in Pre-Clinical MASH Models

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company listed on Nasdaq under the ticker symbol NRBO, announced promising pre-clinical data on May 22, 2024. The findings indicate that DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, shows significant potential in treating liver conditions when combined with semaglutide (Wegovy®). Specifically, the combination has been found to improve liver fibrosis and exhibit additive hepatoprotective effects in models of metabolic dysfunction-associated steatohepatitis (MASH) more effectively than either treatment used alone.

These compelling results will be shared through two poster presentations at the EASL Congress 2024, scheduled to take place from June 5-8, both in Milan, Italy, and virtually. The presentations will be conducted by members of the Dong-A ST Research Center and Gubra, a Contract Research Organization.

Key metrics for evaluating the effectiveness of DA-1241 in combination with semaglutide include the NAFLD Activity Score and Lobular Inflammation Score, which assess the severity of non-alcoholic fatty liver disease. Additionally, the impact on liver fibrosis induced by CCI4 (carbon tetrachloride) will be examined. These metrics collectively underscore the potential of this combination treatment in addressing complex liver conditions effectively.

NeuroBo Pharmaceuticals is focused on developing transformative treatments for cardiometabolic diseases. The promising pre-clinical data suggests that DA-1241, especially when used alongside semaglutide, could be a significant advancement in the treatment of MASH, a severe liver condition. Liver fibrosis, a hallmark of MASH and other liver diseases, involves the excessive accumulation of extracellular matrix proteins, leading to scarring and impaired liver function. By ameliorating liver fibrosis and offering added protective benefits to the liver, the combination of DA-1241 and semaglutide could represent a new therapeutic approach for patients suffering from liver-related metabolic dysfunction.

The upcoming presentations at the EASL Congress 2024 are highly anticipated in the medical community, as they will provide deeper insights into the efficacy and potential application of this combination therapy. Researchers and healthcare professionals attending the congress will have the opportunity to examine the detailed data and discuss the implications for future clinical trials and potential treatments.

Overall, NeuroBo Pharmaceuticals' announcement highlights a significant step forward in the development of novel treatments for liver diseases. The collaborative effort between NeuroBo Pharmaceuticals, Dong-A ST Research Center, and Gubra demonstrates the importance of combined expertise in advancing medical research. The findings presented at the EASL Congress 2024 will likely stimulate further research and development in the field of hepatology, potentially leading to more effective and comprehensive treatments for patients with MASH and other liver conditions.